Stocks and Investing
Stocks and Investing
Tue, February 1, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BNTX) at Hold with Decreased Target to $217 on, Feb 1st, 2022
Matthew Harrison of Morgan Stanley, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $284 to $217 on, Feb 1st, 2022.
Matthew has made no other calls on BNTX in the last 4 months.
There are 4 other peers that have a rating on BNTX. Out of the 4 peers that are also analyzing BNTX, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $225 on, Tuesday, November 9th, 2021
- Akash Tewari of "Jefferies" Initiated at Hold and Held Target at $230 on, Thursday, October 7th, 2021
- Daina Graybosch of "SVB Leerink" Maintained at Hold with Decreased Target to $268 on, Tuesday, October 5th, 2021
This is the rating of the analyst that currently disagrees with Matthew
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $366 on, Tuesday, December 21st, 2021
Contributing Sources